ELIQUIS
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- ELIQUIS
- Generic name
- APIXABAN
- Manufacturer
- Aphena Pharma Solutions - Tennessee, LLC
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 41a133ef-e461-48ad-8221-b735bdd0ec25
- SPL ID
- 5c3dd175-ba67-d91d-e063-6294a90a045d
- Version
- 5
- Effective date
- 2026-09-24
- Source export date
- 2026-11-13
- Source partition
- 7
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0007-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/875ce92e4370b2000cf566c8a9c0e4d02cceccd3a3b18a8b0b87928b28506f0b/drug-label-0007-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 16:34:56
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | NDA | 202155 | derived:openfda.application_number |
| application number | NDA202155 | openfda.application_number | |
| brand name | ELIQUIS | openfda.brand_name | |
| generic name | APIXABAN | openfda.generic_name | |
| manufacturer name | Aphena Pharma Solutions - Tennessee, LLC | openfda.manufacturer_name | |
| ndc | package | 71610-662-80 | openfda.package_ndc |
| ndc | package | 71610-662-09 | openfda.package_ndc |
| ndc | package | 71610-662-18 | openfda.package_ndc |
| ndc | package | 71610-662-42 | openfda.package_ndc |
| ndc | product | 71610-662 | openfda.product_ndc |
| ndc11 | package | 71610066218 | derived:openfda.package_ndc |
| ndc11 | package | 71610066209 | derived:openfda.package_ndc |
| ndc11 | package | 71610066242 | derived:openfda.package_ndc |
| ndc11 | package | 71610066280 | derived:openfda.package_ndc |
| rxcui | 1364445 | openfda.rxcui | |
| rxcui | 1364447 | openfda.rxcui | |
| spl id | 5c3dd175-ba67-d91d-e063-6294a90a045d | id | |
| spl set id | 41a133ef-e461-48ad-8221-b735bdd0ec25 | set_id | |
| unii | 3Z9Y7UWC1J | openfda.unii |
Boxed warning cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS (B) SPINAL/EPIDURAL HEMATOMA (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. If anticoagulation with ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant [see Dosage and Administration (2.4) , Warnings and Precautions (5.1) , and Clinical Studies (14.1) ] . (B) SPINAL/EPIDURAL HEMATOMA Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: use of indwelling epidural catheters concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants a history of traumatic or repeated epidural or spinal punctures a history of spinal deformity or spinal surgery optimal timing between the administration of ELIQUIS and neuraxial procedures is not known [see Warnings and Precautions (5.3) ] Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary [see Warnings and Precautions (5.3) ] . Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated [see Warnings and Precautions (5.3) ] . WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS (B) SPINAL/EPIDURAL HEMATOMA See full prescribing information for complete boxed warning. (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS: Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. To reduce this risk, consider coverage with another anticoagulant if ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy. (2.4 , 5.1 , 14.1) (B) SPINAL/EPIDURAL HEMATOMA: Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. (5.3)
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings and cautions
5 WARNINGS AND PRECAUTIONS ELIQUIS can cause serious, potentially fatal, bleeding. Promptly evaluate signs and symptoms of blood loss. An agent to reverse the anti-factor Xa activity of apixaban is available. (5.2) Prosthetic heart valves: ELIQUIS use not recommended. (5.4) Increased Risk of Thrombosis in Patients with Triple Positive Antiphospholipid Syndrome: ELIQUIS use not recommended. (5.6) 5.1 Increased Risk of Thrombotic Events after Premature Discontinuation Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from ELIQUIS to warfarin in clinical trials in atrial fibrillation patients. If ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant [see Dosage and Administration (2.4) and Clinical Studies (14.1) ] . 5.2 Bleeding ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding [see Dosage and Administration (2.1) and Adverse Reactions (6.1) ] . Concomitant use of drugs affecting hemostasis increases the risk of bleeding. These include aspirin and other antiplatelet agents, other anticoagulants, heparin, thrombolytic agents, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and nonsteroidal anti-inflammatory drugs (NSAIDs) [see Drug Interactions (7.3) ] . Advise patients of signs and symptoms of blood loss and to report them immediately or go to an emergency room. Discontinue ELIQUIS in patients with active pathological hemorrhage. Reversal of Anticoagulant Effect An agent to reverse the anti-factor Xa activity of apixaban is available. The pharmacodynamic effect of ELIQUIS can be expected to persist for at least 24 hours after the last dose, i.e., for about two drug half-lives. Prothrombin complex concentrate (PCC), activated prothrombin complex concentrate or recombinant factor VIIa may be considered, but have not been evaluated in clinical studies [see Clinical Pharmacology (12.2) ] . When PCCs are used, monitoring for the anticoagulation effect of apixaban using a clotting test (PT, INR, or aPTT) or anti-factor Xa (FXa) activity is not useful and is not recommended. Activated oral charcoal reduces absorption of apixaban, thereby lowering apixaban plasma concentration [see Overdosage (10)] . Hemodialysis does not appear to have a substantial impact on apixaban exposure [see Clinical Pharmacology (12.3) ] . Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of apixaban. There is no experience with antifibrinolytic agents (tranexamic acid, aminocaproic acid) in individuals receiving apixaban. There is no experience with systemic hemostatics (desmopressin) in individuals receiving ELIQUIS, and they are not expected to be effective as a reversal agent. 5.3 Spinal/Epidural Anesthesia or Puncture When neuraxial anesthesia (spinal/epidural anesthesia) or spinal/epidural puncture is employed, patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis. The risk of these events may be increased by the postoperative use of indwelling epidural catheters or the concomitant use of medicinal products affecting hemostasis. Indwelling epidural or intrathecal catheters should not be removed earlier than 24 hours after the last administration of ELIQUIS. The next dose of ELIQUIS should not be administered earlier than 5 hours after the removal of the catheter. The risk may also be increased by traumatic or repeated epidural or spinal puncture. If traumatic puncture occurs, delay the administration of ELIQUIS for 48 hours. Monitor patients frequently for signs and symptoms of neurological impairment (e.g., numbness or weakness of the legs, or bowel or bladder dysfunction). If neurological compromise is noted, urgent diagnosis and treatment is necessary. Prior to neuraxial intervention the physician should consider the potential benefit versus the risk in anticoagulated patients or in patients to be anticoagulated for thromboprophylaxis. 5.4 Patients with Prosthetic Heart Valves The safety and efficacy of ELIQUIS have not been studied in patients with prosthetic heart valves. Therefore, use of ELIQUIS is not recommended in these patients. 5.5 Acute PE in Hemodynamically Unstable Patients or Patients who Require Thrombolysis or Pulmonary Embolectomy Initiation of ELIQUIS is not recommended as an alternative to unfractionated heparin for the initial treatment of patients with PE who present with hemodynamic instability or who may receive thrombolysis or pulmonary embolectomy. 5.6 Increased Risk of Thrombosis in Patients with Triple Positive Antiphospholipid Syndrome Direct-acting oral anticoagulants (DOACs), including ELIQUIS, are not recommended for use in patients with triple-positive antiphospholipid syndrome (APS). For patients with APS (especially those who are triple positive [positive for lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy.
warnings and cautions
5.1 Increased Risk of Thrombotic Events after Premature Discontinuation Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from ELIQUIS to warfarin in clinical trials in atrial fibrillation patients. If ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant [see Dosage and Administration (2.4) and Clinical Studies (14.1) ] .
warnings and cautions
5.2 Bleeding ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding [see Dosage and Administration (2.1) and Adverse Reactions (6.1) ] . Concomitant use of drugs affecting hemostasis increases the risk of bleeding. These include aspirin and other antiplatelet agents, other anticoagulants, heparin, thrombolytic agents, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and nonsteroidal anti-inflammatory drugs (NSAIDs) [see Drug Interactions (7.3) ] . Advise patients of signs and symptoms of blood loss and to report them immediately or go to an emergency room. Discontinue ELIQUIS in patients with active pathological hemorrhage. Reversal of Anticoagulant Effect An agent to reverse the anti-factor Xa activity of apixaban is available. The pharmacodynamic effect of ELIQUIS can be expected to persist for at least 24 hours after the last dose, i.e., for about two drug half-lives. Prothrombin complex concentrate (PCC), activated prothrombin complex concentrate or recombinant factor VIIa may be considered, but have not been evaluated in clinical studies [see Clinical Pharmacology (12.2) ] . When PCCs are used, monitoring for the anticoagulation effect of apixaban using a clotting test (PT, INR, or aPTT) or anti-factor Xa (FXa) activity is not useful and is not recommended. Activated oral charcoal reduces absorption of apixaban, thereby lowering apixaban plasma concentration [see Overdosage (10)] . Hemodialysis does not appear to have a substantial impact on apixaban exposure [see Clinical Pharmacology (12.3) ] . Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of apixaban. There is no experience with antifibrinolytic agents (tranexamic acid, aminocaproic acid) in individuals receiving apixaban. There is no experience with systemic hemostatics (desmopressin) in individuals receiving ELIQUIS, and they are not expected to be effective as a reversal agent.
warnings and cautions
5.4 Patients with Prosthetic Heart Valves The safety and efficacy of ELIQUIS have not been studied in patients with prosthetic heart valves. Therefore, use of ELIQUIS is not recommended in these patients.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions table
<table cellpadding="2.4pt" width="100%"> <caption>Table 1: Bleeding Events in Patients with Nonvalvular Atrial Fibrillation in ARISTOTLE*</caption> <col width="25%"/> <col width="21%"/> <col width="19%"/> <col width="20%"/> <col width="15%"/> <thead> <tr> <th align="left" styleCode="Botrule Toprule " valign="top"/> <th align="center" styleCode="Botrule Toprule " valign="top">ELIQUIS N=9088 n (per 100 pt-year) </th> <th align="center" styleCode="Botrule Toprule " valign="top">Warfarin N=9052 n (per 100 pt-year) </th> <th align="center" styleCode="Botrule Toprule " valign="top">Hazard Ratio (95% CI) </th> <th align="center" styleCode="Botrule Toprule " valign="top">P-value</th> </tr> </thead> <tbody> <tr> <td styleCode="Toprule " valign="top"> <paragraph>Major <sup>†</sup> </paragraph> </td> <td align="center" styleCode="Toprule " valign="top"> <paragraph>327 (2.13)</paragraph> </td> <td align="center" styleCode="Toprule " valign="top"> <paragraph>462 (3.09)</paragraph> </td> <td align="center" styleCode="Toprule " valign="top"> <paragraph>0.69 (0.60, 0.80)</paragraph> </td> <td align="center" styleCode="Toprule " valign="top"> <paragraph><0.0001</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph> Intracranial (ICH) <sup>‡</sup> </paragraph> </td> <td align="center" valign="top"> <paragraph>52 (0.33)</paragraph> </td> <td align="center" valign="top"> <paragraph>125 (0.82)</paragraph> </td> <td align="center" valign="top"> <paragraph>0.41 (0.30, 0.57)</paragraph> </td> <td align="center" valign="top"> <paragraph>-</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph> Hemorrhagic stroke <sup>§</sup> </paragraph> </td> <td align="center" valign="top"> <paragraph>38 (0.24)</paragraph> </td> <td align="center" valign="top"> <paragraph>74 (0.49)</paragraph> </td> <td align="center" valign="top"> <paragraph>0.51 (0.34, 0.75)</paragraph> </td> <td align="center" valign="top"> <paragraph>-</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph> Other ICH</paragraph> </td> <td align="center" valign="top"> <paragraph>15 (0.10)</paragraph> </td> <td align="center" valign="top"> <paragraph>51 (0.34)</paragraph> </td> <td align="center" valign="top"> <paragraph>0.29 (0.16, 0.51)</paragraph> </td> <td align="center" valign="top"> <paragraph>-</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph> Gastrointestinal (GI) <sup>¶</sup> </paragraph> </td> <td align="center" valign="top"> <paragraph>128 (0.83)</paragraph> </td> <td align="center" valign="top"> <paragraph>141 (0.93)</paragraph> </td> <td align="center" valign="top"> <paragraph>0.89 (0.70, 1.14)</paragraph> </td> <td align="center" valign="top"> <paragraph>-</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph> Fatal**</paragraph> </td> <td align="center" valign="top"> <paragraph>10 (0.06)</paragraph> </td> <td align="center" valign="top"> <paragraph>37 (0.24)</paragraph> </td> <td align="center" valign="top"> <paragraph>0.27 (0.13, 0.53)</paragraph> </td> <td align="center" valign="top"> <paragraph>-</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph> Intracranial</paragraph> </td> <td align="center" valign="top"> <paragraph>4 (0.03)</paragraph> </td> <td align="center" valign="top"> <paragraph>30 (0.20)</paragraph> </td> <td align="center" valign="top"> <paragraph>0.13 (0.05, 0.37)</paragraph> </td> <td align="center" valign="top"> <paragraph>-</paragraph> </td> </tr> <tr> <td styleCode="Botrule " valign="top"> <paragraph> Non-intracranial</paragraph> </td> <td align="center" styleCode="Botrule " valign="top"> <paragraph>6 (0.04)</paragraph> </td> <td align="center" styleCode="Botrule " valign="top"> <paragraph>7 (0.05)</paragraph> </td> <td align="center" styleCode="Botrule " valign="top"> <paragraph>0.84 (0.28, 2.15)</paragraph> </td> <td align="center" styleCode="Botrule " valign="top"> <paragraph>-</paragraph> </td> </tr> </tbody> </table>
adverse reactions table
<table cellpadding="2.4pt" width="100%"> <caption>Table 2: Bleeding Events in Patients with Nonvalvular Atrial Fibrillation in AVERROES</caption> <col width="25%"/> <col width="20%"/> <col width="20%"/> <col width="20%"/> <col width="15%"/> <thead> <tr> <th align="left" styleCode="Botrule Toprule " valign="top"/> <th align="center" styleCode="Botrule Toprule " valign="top">ELIQUIS N=2798 n (%/year) </th> <th align="center" styleCode="Botrule Toprule " valign="top">Aspirin N=2780 n (%/year) </th> <th align="center" styleCode="Botrule Toprule " valign="top">Hazard Ratio (95% CI) </th> <th align="center" styleCode="Botrule Toprule " valign="top">P-value</th> </tr> </thead> <tfoot> <tr> <td align="left" colspan="10" styleCode="Botrule" valign="top">Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.</td> </tr> </tfoot> <tbody> <tr> <td styleCode="Toprule " valign="top"> <paragraph>Major</paragraph> </td> <td align="center" styleCode="Toprule " valign="top"> <paragraph>45 (1.41)</paragraph> </td> <td align="center" styleCode="Toprule " valign="top"> <paragraph>29 (0.92)</paragraph> </td> <td align="center" styleCode="Toprule " valign="top"> <paragraph>1.54 (0.96, 2.45)</paragraph> </td> <td align="center" styleCode="Toprule " valign="top"> <paragraph>0.07</paragraph> </td> </tr> <tr> <td valign="top"> <paragraph> Fatal</paragraph> </td> <td align="center" valign="top"> <paragraph>5 (0.16)</paragraph> </td> <td align="center" valign="top"> <paragraph>5 (0.16)</paragraph> </td> <td align="center" valign="top"> <paragraph>0.99 (0.23, 4.29)</paragraph> </td> <td align="center" valign="top"> <paragraph>-</paragraph> </td> </tr> <tr> <td styleCode="Botrule " valign="top"> <paragraph> Intracranial</paragraph> </td> <td align="center" styleCode="Botrule " valign="top"> <paragraph>11 (0.34)</paragraph> </td> <td align="center" styleCode="Botrule " valign="top"> <paragraph>11 (0.35)</paragraph> </td> <td align="center" styleCode="Botrule " valign="top"> <paragraph>0.99 (0.39, 2.51)</paragraph> </td> <td align="center" styleCode="Botrule " valign="top"> <paragraph>-</paragraph> </td> </tr> </tbody> </table>
adverse reactions table
<table cellpadding="5.75pt" width="99.88%"> <caption>Table 3: Bleeding During the Treatment Period in Patients Undergoing Elective Hip or Knee Replacement Surgery</caption> <col width="14%"/> <col width="15%"/> <col width="14%"/> <col width="15%"/> <col width="13%"/> <col width="15%"/> <col width="15%"/> <thead> <tr> <th align="left" styleCode="Rrule Botrule Toprule " valign="top"> <content styleCode="bold">Bleeding Endpoint*</content> </th> <th align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top"> <content styleCode="bold">ADVANCE-3 Hip Replacement Surgery </content> </th> <th align="center" colspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="top"> <content styleCode="bold">ADVANCE-2 Knee Replacement Surgery </content> </th> <th align="center" colspan="2" styleCode="Botrule Lrule Toprule " valign="top"> <content styleCode="bold">ADVANCE-1 Knee Replacement Surgery </content> </th> </tr> </thead> <tfoot> <tr> <td align="left" colspan="7" styleCode="Botrule" valign="top">* All bleeding criteria included surgical site bleeding. <sup>†</sup> Includes 13 subjects with major bleeding events that occurred before the first dose of ELIQUIS (administered 12 to 24 hours post-surgery). <sup>‡</sup> Includes 5 subjects with major bleeding events that occurred before the first dose of ELIQUIS (administered 12 to 24 hours post-surgery). <sup>§</sup> Intracranial, intraspinal, intraocular, pericardial, an operated joint requiring re-operation or intervention, intramuscular with compartment syndrome, or retroperitoneal. Bleeding into an operated joint requiring re-operation or intervention was present in all patients with this category of bleeding. Events and event rates include one enoxaparin-treated patient in ADVANCE-1 who also had intracranial hemorrhage. <sup>¶</sup> CRNM = clinically relevant nonmajor. </td> </tr> </tfoot> <tbody> <tr> <td rowspan="2" styleCode="Rrule Toprule " valign="top"/> <td align="center" styleCode="Rrule Lrule Toprule " valign="top"> <paragraph>ELIQUIS 2.5 mg po bid 35±3 days </paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule " valign="top"> <paragraph>Enoxaparin 40 mg sc qd 35±3 days </paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule " valign="top"> <paragraph>ELIQUIS 2.5 mg po bid 12±2 days </paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule " valign="top"> <paragraph>Enoxaparin 40 mg sc qd 12±2 days </paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule " valign="top"> <paragraph>ELIQUIS 2.5 mg po bid 12±2 days </paragraph> </td> <td align="center" styleCode="Lrule Toprule Botrule " valign="top"> <paragraph>Enoxaparin 30 mg sc q12h 12±2 days </paragraph> </td> </tr> <tr> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>First dose 12 to 24 hours post surgery </paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>First dose 9 to 15 hours prior to surgery </paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>First dose 12 to 24 hours post surgery </paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>First dose 9 to 15 hours prior to surgery </paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>First dose 12 to 24 hours post surgery </paragraph> </td> <td align="center" styleCode="Lrule Toprule Botrule " valign="top"> <paragraph>First dose 12 to 24 hours post surgery </paragraph> </td> </tr> <tr> <td styleCode="Rrule Toprule Botrule " valign="top"> <paragraph>All treated</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>N=2673</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>N=2659</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>N=1501</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>N=1508</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>N=1596</paragraph> </td> <td align="center" styleCode="Lrule Toprule Botrule " valign="top"> <paragraph>N=1588</paragraph> </td> </tr> <tr> <td styleCode="Rrule Toprule Botrule " valign="top"> <paragraph>Major (including surgical site)</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>22 (0.82%) <sup>†</sup> </paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>18 (0.68%)</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>9 (0.60%) <sup>‡</sup> </paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>14 (0.93%)</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>11 (0.69%)</paragraph> </td> <td align="center" styleCode="Lrule Toprule Botrule " valign="top"> <paragraph>22 (1.39%)</paragraph> </td> </tr> <tr> <td styleCode="Rrule Toprule Botrule " valign="top"> <paragraph> Fatal</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>0</paragraph> </td> <td align="center" styleCode="Lrule Toprule Botrule " valign="top"> <paragraph>1 (0.06%)</paragraph> </td> </tr> <tr> <td styleCode="Rrule Toprule Botrule " valign="top"> <paragraph> Hgb decrease ≥2 g/dL</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>13 (0.49%)</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>10 (0.38%)</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>8 (0.53%)</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>9 (0.60%)</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>10 (0.63%)</paragraph> </td> <td align="center" styleCode="Lrule Toprule Botrule " valign="top"> <paragraph>16 (1.01%)</paragraph> </td> </tr> <tr> <td styleCode="Rrule Toprule Botrule " valign="top"> <paragraph> Transfusion of ≥2 units RBC</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>16 (0.60%)</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>14 (0.53%)</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>5 (0.33%)</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>9 (0.60%)</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>9 (0.56%)</paragraph> </td> <td align="center" styleCode="Lrule Toprule Botrule " valign="top"> <paragraph>18 (1.13%)</paragraph> </td> </tr> <tr> <td styleCode="Rrule Toprule Botrule " valign="top"> <paragraph> Bleed at critical site <sup>§</sup> </paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>1 (0.04%)</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>1 (0.04%)</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>1 (0.07%)</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>2 (0.13%)</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>1 (0.06%)</paragraph> </td> <td align="center" styleCode="Lrule Toprule Botrule " valign="top"> <paragraph>4 (0.25%)</paragraph> </td> </tr> <tr> <td styleCode="Rrule Toprule Botrule " valign="top"> <paragraph>Major + CRNM <sup>¶</sup> </paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>129 (4.83%)</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>134 (5.04%)</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>53 (3.53%)</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>72 (4.77%)</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>46 (2.88%)</paragraph> </td> <td align="center" styleCode="Lrule Toprule Botrule " valign="top"> <paragraph>68 (4.28%)</paragraph> </td> </tr> <tr> <td styleCode="Rrule Botrule Toprule " valign="top"> <paragraph>All</paragraph> </td> <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top"> <paragraph>313 (11.71%)</paragraph> </td> <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top"> <paragraph>334 (12.56%)</paragraph> </td> <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top"> <paragraph>104 (6.93%)</paragraph> </td> <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top"> <paragraph>126 (8.36%)</paragraph> </td> <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top"> <paragraph>85 (5.33%)</paragraph> </td> <td align="center" styleCode="Botrule Lrule Toprule " valign="top"> <paragraph>108 (6.80%)</paragraph> </td> </tr> </tbody> </table>
adverse reactions table
<table width="100%"> <caption>Table 4: Adverse Reactions Occurring in ≥1% of Patients in Either Group Undergoing Hip or Knee Replacement Surgery</caption> <col width="55%"/> <col width="20%"/> <col width="25%"/> <thead> <tr> <th align="left" styleCode="Rrule Botrule Toprule " valign="top"/> <th align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top"> <content styleCode="bold">ELIQUIS, n (%) 2.5 mg po bid N=5924 </content> </th> <th align="center" styleCode="Botrule Lrule Toprule " valign="top"> <content styleCode="bold">Enoxaparin, n (%) 40 mg sc qd or 30 mg sc q12h N=5904 </content> </th> </tr> </thead> <tbody> <tr> <td styleCode="Rrule Toprule Botrule " valign="top"> <paragraph>Nausea</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>153 (2.6)</paragraph> </td> <td align="center" styleCode="Lrule Toprule Botrule " valign="top"> <paragraph>159 (2.7)</paragraph> </td> </tr> <tr> <td styleCode="Rrule Toprule Botrule " valign="top"> <paragraph>Anemia (including postoperative and hemorrhagic anemia, and respective laboratory parameters)</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>153 (2.6)</paragraph> </td> <td align="center" styleCode="Lrule Toprule Botrule " valign="top"> <paragraph>178 (3.0)</paragraph> </td> </tr> <tr> <td styleCode="Rrule Toprule Botrule " valign="top"> <paragraph>Contusion</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>83 (1.4)</paragraph> </td> <td align="center" styleCode="Lrule Toprule Botrule " valign="top"> <paragraph>115 (1.9)</paragraph> </td> </tr> <tr> <td styleCode="Rrule Toprule Botrule " valign="top"> <paragraph>Hemorrhage (including hematoma, and vaginal and urethral hemorrhage)</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>67 (1.1)</paragraph> </td> <td align="center" styleCode="Lrule Toprule Botrule " valign="top"> <paragraph>81 (1.4)</paragraph> </td> </tr> <tr> <td styleCode="Rrule Toprule Botrule " valign="top"> <paragraph>Postprocedural hemorrhage (including postprocedural hematoma, wound hemorrhage, vessel puncture-site hematoma, and catheter-site hemorrhage)</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>54 (0.9)</paragraph> </td> <td align="center" styleCode="Lrule Toprule Botrule " valign="top"> <paragraph>60 (1.0)</paragraph> </td> </tr> <tr> <td styleCode="Rrule Toprule Botrule " valign="top"> <paragraph>Transaminases increased (including alanine aminotransferase increased and alanine aminotransferase abnormal)</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>50 (0.8)</paragraph> </td> <td align="center" styleCode="Lrule Toprule Botrule " valign="top"> <paragraph>71 (1.2)</paragraph> </td> </tr> <tr> <td styleCode="Rrule Toprule Botrule " valign="top"> <paragraph>Aspartate aminotransferase increased</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>47 (0.8)</paragraph> </td> <td align="center" styleCode="Lrule Toprule Botrule " valign="top"> <paragraph>69 (1.2)</paragraph> </td> </tr> <tr> <td styleCode="Rrule Botrule Toprule " valign="top"> <paragraph>Gamma-glutamyltransferase increased</paragraph> </td> <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top"> <paragraph>38 (0.6)</paragraph> </td> <td align="center" styleCode="Botrule Lrule Toprule " valign="top"> <paragraph>65 (1.1)</paragraph> </td> </tr> </tbody> </table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.